How did BNR's earnings perform in Q2 2024 compared to previous quarters?

Burning Rock Biotech (BNR) experienced a significant decline in net income in Q2 2024 compared to the previous quarters of Q1 2024 and Q3 2024. 1. **Q2 2024 Performance**: - BNR reported a net income of -$14.87 million for Q2 2024. 2. **Comparison with Q1 2024**: - In Q1 2024, BNR had a net income of -$16.83 million. - The net income in Q2 2024 showed an improvement compared to Q1 2024, as the net loss decreased by approximately $2 million. 3. **Comparison with Q3 2024**: - For Q3 2024, BNR reported a net income of -$35.7 million. - The net income in Q2 2024 was significantly better than Q3 2024, showing an improvement of over $20 million in net income. 4. **Revenue Trends**: - Total revenues for Q2 2024 were RMB135.5 million (US$18.7 million), representing a 7.3% decrease from RMB146.3 million for the same period in 2023. - The transition from central-lab to more in-hospital based testing was a significant factor in the revenue decrease. In summary, while BNR's net income in Q2 2024 improved compared to Q1 2024, it was still negative and significantly lower than the net income in Q3 2024. The company's strategic shifts in testing services and the impact of market conditions are key factors influencing its financial performance.